Abacavir Conference Data

Medical Advocates
Abacavir (Ziagen)

Conference Citations

XVII International AIDS Conference
15th CROI
4th IAS Conference
14th CROI
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
13th CROI
3rd IAS Conference
Conference Archives

Abacavir Main Page Main New/Newsworthy Home Page

Last updated: September 10, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Perinatal Data are integrated with Perinatal Conference Data in the Perinatal Data Page. Pediatric
Data are integrated with Pediatric Conference Data in the Pediatric Data Page
ABC/3TC/ZDV data are indexed on the Trizavir Web

XVII International AIDS Conference

NEWS RELEASE
Pooled-Analysis of 54 Clinical Studies Shows No Increased Risk of Heart Attack With Abacavir Therapy
GSK August 6, 2008

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
enrolled in the SMART study
J. Lundgren, J. Neuhaus, A. Babiker, et al
Abstract

Prospective HLA-B*5701 screening for abacavir hypersensitivity saves costs
E. Wolf , M. Stoll , M. Becker-Andre, et al
Abstract
Adverse drug events in HIV: patch test and hypersensitivity reaction to abacavir (HSR-ABC)
S. Giorgini , C. Martinelli , A. Carocci , et al
Abstract

HLA-B*5701 screening reduces abacavir hypersensitivity reactions (ABC HSR); multiple lines of evidence to
establish a new standard of care
P. Wannamaker, S. Mallal, E. Phillips, et al
Abstract

15th Conference on Retroviruses and
Opportunistic Infections

Do Thymidine Analogues, Abacavir, Didanosine and Lamivudine Contribute to the Risk of Myocardial
Infarction? The D:A:D Study
C Sabin, S Worm, R Weber, et al
Abstract

A WEEK IN REVIEW FEATURED REPORT
Outcomes of Abacavir- and Efavirenz-based HAART: Comparison of ACTG 5095 Trial Results
with Observational Cohort Studies
M Mugavero, M May, H Ribaudo, et al
Abstract

CONFERENCE PDF POSTER
Changes in Body Composition Attributable to Lamivudine, Stavudine, Zidovudine, and Abacavir
in HIV-infected Persons Initiating ART
J Shlay, S Sharma, G Bartsch, et al
PDF Poster Abstract

Pharmacological Mechanisms Leading to Early Virologic Failure of 2 Antiretroviral Regimens:
Didanosine, Lamivudine, and Tenofovir, and Abacavir, Lamivudine, and Tenofovir
LBi, J Russel, N Mordwinkin, et al
Abstract

Genetic Factors Predicting Abacavir Hypersensitivity and Tolerance in HLA-B*5701⁺ Individuals:
Combined Analysis from PREDICT-1, SHAPE, and a Multinational Study
D Nolan, D Thorborn, M Schaefer, et al
Abstract

Genetic Testing in HIV Care: Clinical Effect and Cost-effectiveness of HLA-B*5701 Screening to
Guide First-line Abacavir Use
B Schackman, C Scott, R Walensky, et al
Abstract

HCP5-Single Nucleotide Polymorphism: A Simple Screening Tool for Predicting Abacavir
Hypersensitivity Reactions
S Colombo, A Rauch, M Rotger, et al
Abstract

Selection of K65R Mutation in HIV-2 Patients Exposed to Abacavir
B Rodes, C Toro, R Colombatti, et al
Abstract

4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

An open-label, two-period, crossover, pharmacokinetic (PK) study of abacavir (ABC) and its
intracellular anabolite carbovir triphosphate (CBV-TP) following 600mg once-daily (QD) and
300mg twice-daily (BD) administration of abacavir in HIV-infected subjects
Moyle G, Fletcher C, Higgs C, et al
Abstract

High sensitivity of HLA-B*5701 in Whites and Blacks in immunologically-confirmed cases of
abacavir hypersensitivity (ABC HSR)
Saag M, Balu R, Brachman P, et al
Abstract

How effectively HLA screaning can reduce the early discontinuation of abacavir in real life?
Trottier B, Thomas R, Nguyen VK, Machouf N. et al
Abstract

Low incidence of abacavir-associated hypersensitivity reactions in Japanese HIV-1-infected
patients
Honda H, Tsukada K, Yazaki H, et al
Abstract

Abacavir hypersensitivity and HLA typing of HIV-infected patients in Taiwan
Sun H-Y, Liu W-C, Wu C-H, et al
Abstract

PREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B*5701
screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030)
Mallal S, Phillips E, Carosi G, et al
Abstract

Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir administered
with abacavir/lamivudine (KIVEXA) in antiretroviral-na�ve patients: a multicentre,
randomized study (LAKE study)
Echeverria P, Alonso MM, Portilla J, et al
Abstract

Multi-centre evaluation of HLA-B*5701 allele detection by SSP-PCR typing: a quality assurance
initiative
Hammond E, Almeida C, Mamotte C, et al
Abstract

Genetic characterization of patients with MHC class I mediated abacavir hypersensitivity
reaction
Phillips E, Rauch A, Nolan D, et al
Abstract

A rapid and sensitive flow-based screening test for detection of HLA-B57 to avoid abacavir
hypersensitivity
Kostenko L, Lucas A, Kjer-Nielsen L, et al
Abstract

Use of the ELISpot assay to detect abacavir- and nevirapine-induced IFN-g responses in PBMC
from HIV-infected patients with abacavir or nevirapine hypersensitivity reactions
Keane N, Lucas A, Netto J, et al
Abstract

Abacavir hypersensitivity and HLA-B*5701 carriage in a Caribbean cohort
Abel S, Bera O, Pierre-Francois S, et al
Abstract

Abacavir hypersensitivity in HLA-B57-positive individuals with HIV infection is dependent upon
the conventional MHC-I Ag presentation pathway
McCluskey J1, Chessman D, Lethborg T, et al
Abstract

HLA-B*5701 carriage: preliminary result in a Caribbean cohort of HIV-infected patients
Abel S, Paturel L, Pierre-Francois S, et al
Abstract

14th Conference on Retroviruses and
Opportunistic Infections

Abacavir Plasma Pharmacokinetics in the Absence and the Presence of Atazanavir/Ritonavir or
Lopinavir/Ritonavir) and Vice Versa in HIV⁺ Patients
Laura Waters, G Moyle, A D�Avolio, et al
Abstract

8th Int Congress on Drug Therapy in HIV Infection

Screening for HLA B5701 in a population of HIV patients of diverse ethnic origin exposed
to abacavir in France
D Zucman, P De Truchis, C Majerholc, et al
Abstract
HLA-B5701 testing and abacavir hypersensitivity: a single centre experience
L Waters, A Gritz, D Maitland
Abstract
Value of the HLAB*5701 allele to predict abacavir hypersensitivity in Spaniards
S Rodriguez-Novoa, P Garcia, G Gonzalez, et al
Abstract
Abacavir hypersensitivity reaction in EuroSIDA
W Bannister, N Friis-M�ller, A Mocroft, et al
Abstract
Comparison of efficacy and toxicity profile of abacavir (ABA) and tenofovir (TDF) containing
regimens
C Smith, M Nelson, M Fisher, et al
Abstract
Study of changes in CD4 cells count after switching tenofovir to abacavir or TDF and didanosine to
ABC+ lamivudine in patients with a ddI+TDF containing regimen and viral suppression (Europa study):
preliminary analysis
E Pedrol, E Negredo, P Domingo, et al
Abstract
Outcomes of antiretroviral regimens containing Abacavir (ABC) with Tenofovir (TDF) in treatment-
experienced patients: predictors of response and drug resistance evolution in failing patients
S Di Giambenedetto, C Torti, F Castelnuovo, et al
Abstract
Genotypic resistance in HIV+ naive patients enrolled in a 96-week randomized trial comparing
abacavir (ABC) vs. stavudine (d4T), both combined with lamivudine/efavirenz (3TC/EFV)
E Ferrer, J Niubo, D Podzamczer, et al
Abstract
Abacavir-associated drug hypersensitivity is strongly associated with the human leukocyte
antigen B-57 allele
N Tesch, M Vogel, JC Wasmuth, et al
Abstract

XVI International AIDS Conference

Pharmacogenetic (PG) investigation of hypersensitivity to abacavir
M. Mosteller, A. Hughes, L. Warren, et al
Abstract

13th Conference on Retroviruses and
Opportunistic Infections

Safety of Nevirapine Compared to Abacavir on a Background of Zidovudine/Lamivudine as
First-line Antiretroviral Therapy: A Randomized Double-blind Trial
P Munderi and the DART Trial Team
Abstract
Molecular Mechanism of Tenofovir, Abacavir, and Lamivudine Resistance by the K70E Mutation in HIV-1 Reverse Transcriptase
Nicolas Sluis-Cremer, P Argoti Torres, J Grzybowski, et al
Abstract
POSTER
T215F Mutation and Abacavir or Efavirenz Use Are Linked to the L74I Mutation Selection
M Wirden, AG Marcelin, J Ghosn, et al
PDF Poster Abstract

3rd IAS Conference

Frequency of Abacavir (ABC) Hypersensitivity Reactions (HSR), Rechallenge Reactions, and
HSR-Attributable Outcomes are similar with the use of Ziagen or Trizivir: Final Results from the
Trizivir Epidemiology Study
Bartlett JA., Mole LA., Fusco JS, et al
Abstract
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human
Immunodeficiency Virus Infection: Definitive Three-Year Results of the NEFA Study.
Mart�nez E., Arnaiz J.A., Podzamcer D., et al
Abstract
Chronic in vitro abacavir exposure elicits an immunological response in abacavir
naive HIV-positive individuals
Almeida C.-A., Martin A., Nolan D., et al
Abstract

Abacavir Main Page Main New/Newsworthy Home Page

Abacavir Conference Citations